查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930045

自闭症谱系障碍（ASD）治疗市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2025-2034）

Autism Spectrum Disorder Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 162 Pages | 商品交期: 请询问到货日

价格

自闭症谱系障碍（ASD）治疗市场成长驱动因素

全球自闭症谱系障碍（ASD）治疗市场在2025年达到 22.1亿美元，并预计在预测期内稳定成长。报告显示，该市场预计将从2026年的23.3亿美元成长到2034年的40.6亿美元，2026年至2034年的年复合成长率（CAGR）为 6.51%。该成长趋势得益于 ASD 盛行率的上升、公众意识的提高以及政府主导的目的是早期诊断和增加治疗机会的各项措施。

自闭症谱系障碍（ASD）是一组神经发育障碍，其特征是社交沟通障碍、兴趣狭窄和重复性行为。这些障碍包括自闭症、亚斯伯格症和广泛性发展障碍（PDD）。全球 ASD 诊断率的上升显着增加了对目的是控制行为症状和相关合併症的药物治疗的需求。

市场动态

市场驱动因素

自闭症谱系障碍（ASD）治疗市场的主要驱动因素之一是政府主导的目的是提高公众对 ASD 的认识和早期诊断的举措日益增多。多个地区的政府投资公共教育计画、资助自闭症专项基金会并实施全面的医疗保健政策。这些努力促进了症状的早期发现，并直接增加了对治疗介入的需求。

例如，2025年5月，巴西体育部在国际残疾人权利大会上宣布了一项以自闭症为重点的体育融合计划。此类计画凸显了机构对自闭症谱系障碍（ASD）患者的支持力度不断加大，对治疗的接受度和市场成长产生了积极影响。

市场限制因子

儘管人们对自闭症的认识不断提高，但由于补充和替代疗法（CAM）的普及，市场仍面临一些限制因素。螯合疗法、高压氧疗法、针灸和饮食疗法等治疗方法越来越受到照护者的青睐，限制了传统药物疗法的应用。根据美国儿科学会2023年3月发布的报告，近95%的自闭症谱系障碍儿童至少尝试过一种替代疗法。

市场机会

由于FDA核准的药物供应有限，自闭症谱系障碍治疗市场蕴藏着巨大的机会。目前，仅有利于培酮和阿立哌唑获准用于治疗自闭症谱系障碍（ASD）的药物，但这些药物主要针对易怒和攻击性行为，而非ASD的核心症状。这种未被满足的需求促使製药公司将重点放在针对社交沟通障碍和重复行为的创新疗法上。

市场挑战

自闭症治疗的高成本仍然是一个主要挑战。长期治疗、专家咨询和品牌药物给家庭带来了沉重的经济负担，尤其是在中低收入国家。即使是已获批药物的仿製药价格仍然昂贵，限制了药物的可及性，并减缓了市场渗透。

自闭症谱系障碍（ASD）治疗市场趋势

影响市场发展的关键趋势包括ASD治疗临床研发管线的扩展与创新。多家公司投资新的药理作用机制，包括神经调节疗法、酵素替代疗法、催产素疗法和谷氨酸能药物。越来越多的药物被超适应症使用，进一步凸显了针对自闭症谱系障碍（ASD）核心症状的核准疗法的迫切性。

市场区隔分析

依药物类型

依药物类型划分，市场包括抗精神病药、选择性血清素再摄取抑制剂（SSRI）/抗忧郁药、兴奋剂和助眠药。兴奋剂将在2026年占据市场主导地位，市场占有率达28.65%。这主要是因为它们在控制ASD患者的注意力不足过动症（ADHD）相关症状（例如过动和注意力不集中）方面具有疗效。

依疾病类型

根据疾病分类，自闭症谱系障碍（ASD）将在2026年占据最大的市场占有率，达到55.41%。这主要是由于其高盛行率以及政府支持的干预计画数量的增加。

依年龄层划分

预计儿科市场成长最快，主要得益于早期诊断和家长意识的提高。同时，成人市场在2026年将占总市场的71.3%，反映了成人持续的治疗需求。

依通路划分

医院药局在2026年将占据市场主导地位，市场占有率达39.57%，主要得益于专科处方、保险覆盖及管制药品分发等因素。

区域洞察

预计北美地区在2025年将引领全球自闭症谱系障碍（ASD）治疗市场，创造12.8亿美元的收入，占市场占有率的58.1%。这一主导地位归功于较高的认知度、完善的偿付体系和不断提高的诊断率。预计到2026年，光是美国市场规模就将达到12.6亿美元。

欧洲占第二大市场占有率，这得益于筛检计画的改进和研究措施的推进。同时，亚太地区预计将以最高的年复合成长率成长，这主要得益于公众意识的提高、医疗基础设施的扩张以及日本、中国和印度等国家研究活动的增加。

这份 "自闭症谱系障碍（ASD）治疗市场" 报告对全球产业进行了全面系统的分析，重点在于定性和定量分析。报告内容包括2025年基准年市场规模和价值的详细评估、2026年的预测值、直至2034年的长期预测以及预测期内的相关年复合成长率。

本报告深入分析了市场动态，包括影响市场扩张的关键驱动因素、限制因素、机会和挑战。本报告深入分析了政府措施、宣传活动、定价挑战以及辅助和替代疗法对传统自闭症谱系障碍（ASD）药物应用的影响。

本报告的大部分篇幅用于细分市场分析，涵盖了依药物类型、疾病类型、年龄层和通路划分的市场。每个细分市场都从市场占有率、成长潜力和潜在需求驱动因素等方面进行了分析。基于已发表的资料，本报告还重点介绍了特定细分市场的主导地位，例如兴奋剂、自闭症谱系障碍（ASD）、成人患者和医院药房。

此外，本报告还提供了详细的区域展望，分析了北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的市场表现。区域分析包括市场规模、成长驱动因素、医疗保健基础设施、偿付方案以及适用的国家/地区特定资讯。

此外，本报告还提供了全面的竞争格局分析，包括对主要市场参与者的概况介绍，以及对研发活动、临床管线拓展、合作关係和产品开发等策略措施的评估。报告还涵盖了近期发展动态，以帮助全面了解竞争格局。

总而言之，本报告为自闭症谱系障碍（ASD）治疗市场的当前趋势、未来成长前景和结构动态提供了切实可行的见解，可作为利害关係人的策略资源。

FDA 核准的治疗药物供应有限，凸显了巨大的未满足需求，促使製药公司加强研发和创新力度。同时，不断上涨的治疗成本和对替代疗法的日益依赖，持续对市场渗透构成挑战，尤其是在成本敏感地区。

依地区划分，北美凭藉其先进的医疗保健基础设施和有利的偿付政策，保持着领先地位；而亚太地区则凭藉日益增强的健康意识和不断扩大的研究活动，已成为一个高成长地区。

整体而言，市场前景依然乐观。药物研发的创新、支持性的政策框架以及全球对自闭症护理日益成长的关注，预计将塑造自闭症谱系障碍（ASD）治疗行业到2034年的未来发展轨迹。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第4章 关键考察

  • 主要国家自闭症盛行率（2025年）
  • 主要产业趋势（併购、收购、合作等）
  • 主要国家的监管框架
  • 主要国家/地区自闭症谱系障碍（ASD）治疗的全球偿付和经济负担
  • 主要公司在研产品线分析

第5章 全球自闭症谱系障碍（ASD）治疗药物市场分析、洞察与预测（2021-2034）

  • 依药物类型划分的市场分析、洞察与预测
    • 抗精神病药
    • 选择性血清素再摄取抑制剂/抗忧郁药
    • 兴奋剂
    • 安眠药
    • 其他
  • 依疾病划分的市场分析、洞察与预测
    • 自闭症
    • 亚斯伯格症症候群
    • 广泛性发展障碍（PDD）
    • 其他
  • 市场分析、洞察与预测 - 依年龄层划分
    • 成人
    • 儿科
  • 市场分析、洞察与预测 - 依通路划分
    • 医院药房
    • 药局及零售药房
    • 线上药房
  • 市场分析、洞察与预测 - 依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第6章 北美自闭症谱系障碍（ASD）治疗市场分析、洞察与预测（2021-2034）

  • 依国家/地区
    • 美国
    • 加拿大

第7章 欧洲自闭症谱系障碍（ASD）治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第8章 亚太地区自闭症谱系障碍（ASD）治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 东南亚亚洲
    • 亚太其他地区

第9章 拉丁美洲自闭症谱系障碍（ASD）治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第10章 中东与非洲自闭症谱系障碍（ASD）治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • GCC
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • Curemark, LLC
  • Yamo Pharmaceuticals
  • Pfizer Inc.
  • Eli Lilly and Company
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Otsuka Holdings Co. Ltd.
  • Johnson &Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • H. Lundbeck A/S
Product Code: FBI101207

Growth Factors of autism spectrum disorder (ASD) therapeutics Market

The global autism spectrum disorder (ASD) therapeutics market was valued at USD 2.21 billion in 2025 and is expected to witness steady expansion over the forecast period. According to the report, the market is projected to grow from USD 2.33 billion in 2026 to USD 4.06 billion by 2034, registering a CAGR of 6.51% during 2026-2034. The growth trajectory is supported by the increasing prevalence of autism spectrum disorder, rising awareness among the general population, and expanding government-backed initiatives focused on early diagnosis and treatment access.

Autism spectrum disorder is a group of neurodevelopmental conditions characterized by impairments in social communication, restricted interests, and repetitive behaviors. The condition includes autistic disorder, Asperger's syndrome, and pervasive developmental disorder (PDD). The rising global diagnosis rate of ASD has significantly increased the demand for pharmacological therapies aimed at managing behavioral symptoms and associated comorbidities.

Market Dynamics

Market Drivers

One of the key drivers of the autism spectrum disorder therapeutics market is the growing number of government initiatives to increase awareness and early diagnosis of ASD. Governments across multiple regions are investing in public education programs, funding autism-focused foundations, and implementing inclusive healthcare policies. These initiatives promote early identification of symptoms, which directly increases the demand for therapeutic interventions.

For instance, in May 2025, Brazil's Ministry of Sports presented an autism-focused sports inclusion program at an international disability rights conference. Such programs highlight increasing institutional support for ASD patients, which positively influences treatment uptake and market growth.

Market Restraints

Despite growing awareness, the market faces restraints due to the widespread adoption of complementary and alternative therapies (CAM). Treatments such as chelation therapy, hyperbaric oxygen therapy, acupuncture, and dietary interventions are increasingly preferred by caregivers, limiting the adoption of conventional drug-based therapies. A publication by the American Academy of Pediatrics in March 2023 reported that nearly 95% of children with ASD had tried at least one alternative therapy.

Market Opportunities

The ASD therapeutics market presents significant opportunities due to the limited availability of FDA-approved drugs. Currently, only risperidone and aripiprazole are approved, and they primarily address irritability and aggression rather than core ASD symptoms. This unmet clinical need has encouraged pharmaceutical companies to focus on innovative therapies targeting social communication deficits and repetitive behaviors.

Market Challenges

The high cost of autism treatments remains a major challenge. Long-term therapy, specialist consultations, and branded medications impose a financial burden on families, especially in low- and middle-income countries. Even generic versions of approved drugs remain costly, restricting accessibility and slowing market penetration.

Autism Spectrum Disorder Therapeutics Market Trends

A major trend shaping the market is the expansion of the clinical pipeline and innovation in ASD therapeutics. Several companies are investing in novel drug mechanisms, including neuromodulation, enzyme replacement therapy, oxytocin-based treatments, and glutamatergic agents. The rising use of off-label drugs further underscores the urgent need for approved therapies targeting core ASD symptoms.

Segmentation Analysis

By Drug Type

By drug type, the market includes antipsychotics, SSRIs/antidepressants, stimulants, sleep medications, and others. The stimulants segment dominated the market in 2026, holding a 28.65% share, driven by their effectiveness in managing ADHD-related symptoms such as hyperactivity and inattention in ASD patients.

By Disease Type

Based on disease classification, autistic disorder accounted for the largest share, with 55.41% in 2026, due to its high prevalence and increasing government-supported intervention programs.

By Age Group

The pediatrics segment is expected to witness the fastest growth, supported by early diagnosis and increased parental awareness. The adult segment, however, accounted for 71.3% of total market share in 2026, reflecting continued therapeutic needs among adults.

By Distribution Channel

Hospital pharmacies dominated the market with a 39.57% share in 2026, owing to specialist prescriptions, insurance coverage, and controlled drug dispensing practices.

Regional Insights

North America dominated the global ASD therapeutics market in 2025, generating USD 1.28 billion in revenue and accounting for 58.1% market share. The dominance is attributed to high awareness levels, strong reimbursement frameworks, and increasing diagnosis rates. The U.S. market alone is projected to reach USD 1.26 billion by 2026.

Europe held the second-largest share, supported by improved screening programs and research initiatives. Meanwhile, Asia Pacific is expected to grow at the highest CAGR, driven by rising awareness, expanding healthcare infrastructure, and increasing research activities in countries such as Japan, China, and India.

Competitive Landscape

The autism spectrum disorder therapeutics market is highly fragmented due to the extensive use of off-label drugs. Key players include Otsuka Pharmaceutical, Johnson & Johnson Services, Pfizer, H. Lundbeck, Teva Pharmaceuticals, and AstraZeneca. These companies focus on expanding clinical pipelines, strengthening global distribution networks, and investing in research collaborations to gain a competitive edge.

Report Coverage

The Autism Spectrum Disorder Therapeutics Market report delivers a comprehensive and structured analysis of the global industry, focusing on both qualitative and quantitative insights. The coverage includes a detailed evaluation of market size and value for the base year 2025, estimates for 2026, and long-term projections up to 2034, along with the associated CAGR for the forecast period.

The report thoroughly examines market dynamics, including key drivers, restraints, opportunities, and challenges influencing market expansion. It provides in-depth insights into government initiatives, awareness programs, pricing challenges, and the impact of complementary and alternative therapies on the adoption of conventional ASD therapeutics.

A significant portion of the report is dedicated to segmentation analysis, covering the market by drug type, disease type, age group, and distribution channel. Each segment is analyzed with respect to market share, growth potential, and underlying demand factors. The study also highlights the dominance of specific segments such as stimulants, autistic disorder, adult patients, and hospital pharmacies based on reported data.

The report further presents a detailed regional outlook, analyzing performance across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Regional analysis includes market size, growth drivers, healthcare infrastructure, reimbursement scenarios, and country-level insights where applicable.

Additionally, the coverage includes a robust competitive landscape analysis, profiling key market players and evaluating their strategic initiatives such as research and development activities, clinical pipeline expansion, partnerships, and product development efforts. Recent key industry developments are also included to provide a complete understanding of the competitive environment.

Overall, the report serves as a strategic resource for stakeholders by offering actionable insights into current trends, future growth prospects, and structural dynamics of the autism spectrum disorder therapeutics market.

Conclusion

The global autism spectrum disorder therapeutics market demonstrates steady and sustained growth, supported by increasing diagnosis rates, rising awareness, and expanding government and institutional support across regions. With a market value of USD 2.21 billion in 2025, projected growth to USD 2.33 billion in 2026, and an expected reach of USD 4.06 billion by 2034, the market reflects strong long-term potential.

Limited availability of FDA-approved therapies has highlighted substantial unmet medical needs, encouraging pharmaceutical companies to intensify research and innovation efforts. At the same time, high treatment costs and the growing reliance on alternative therapies continue to pose challenges to market penetration, particularly in cost-sensitive regions.

Regionally, North America maintains a leading position due to advanced healthcare infrastructure and favorable reimbursement policies, while Asia Pacific emerges as a high-growth region driven by improving awareness and expanding research activities.

Overall, the market outlook remains positive, with innovation in drug development, supportive policy frameworks, and increasing global focus on autism care expected to shape the future trajectory of the autism spectrum disorder therapeutics industry through 2034.

Segmentation By Drug Type

  • Antipsychotic Drugs
  • SSRIs/Antidepressants
  • Stimulants
  • Sleep Medications
  • Others

By Disease

  • Autistic Disorder
  • Asperger Syndrome
  • Pervasive Developmental Disorder (PDD)
  • Others

By Age Group

  • Pediatrics
  • Adults

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug Type, By Disease, By Age Group, By Distribution Channel, and by Country/Sub-Regions)
    • U.S.
    • Canada
  • Europe (By Drug Type, By Disease, By Age Group, By Distribution Channel, and by Country/Sub-Regions)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Type, By Disease, By Age Group, By Distribution Channel, and by Country/Sub-Regions)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Type, By Disease, By Age Group, By Distribution Channel, and by Country/Sub-Regions)
    • Brazil
    • Mexico
    • Rest of Latin America
  • The Middle East & Africa (By Drug Type, By Disease, By Age Group, By Distribution Channel, and by Country/Sub-Regions)
    • GCC Countries
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Autism, By Key Countries, 2025
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. Regulatory Framework by Key Countries/Regions
  • 4.4. Global Reimbursement Scenario and Economic Cost Burden for the Treatment of Autism Spectrum Disorder by Key Countries/Region
  • 4.5. Pipeline Analysis, By Key Players

5. Global Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Type
    • 5.1.1. Antipsychotic Drugs
    • 5.1.2. SSRIs/Antidepressants
    • 5.1.3. Stimulants
    • 5.1.4. Sleep Medications
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease
    • 5.2.1. Autistic Disorder
    • 5.2.2. Asperger Syndrome
    • 5.2.3. Pervasive Developmental Disorder (PDD)
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Adults
    • 5.3.2. Pediatrics
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Drug Stores & Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Type
    • 6.1.1. Antipsychotic Drugs
    • 6.1.2. SSRIs/Antidepressants
    • 6.1.3. Stimulants
    • 6.1.4. Sleep Medications
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease
    • 6.2.1. Autistic Disorder
    • 6.2.2. Asperger Syndrome
    • 6.2.3. Pervasive Developmental Disorder (PDD)
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Adults
    • 6.3.2. Pediatrics
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Drug Stores & Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Type
    • 7.1.1. Antipsychotic Drugs
    • 7.1.2. SSRIs/Antidepressants
    • 7.1.3. Stimulants
    • 7.1.4. Sleep Medications
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease
    • 7.2.1. Autistic Disorder
    • 7.2.2. Asperger Syndrome
    • 7.2.3. Pervasive Developmental Disorder (PDD)
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Adults
    • 7.3.2. Pediatrics
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Drug Stores & Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Type
    • 8.1.1. Antipsychotic Drugs
    • 8.1.2. SSRIs/Antidepressants
    • 8.1.3. Stimulants
    • 8.1.4. Sleep Medications
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease
    • 8.2.1. Autistic Disorder
    • 8.2.2. Asperger Syndrome
    • 8.2.3. Pervasive Developmental Disorder (PDD)
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Adults
    • 8.3.2. Pediatrics
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Drug Stores & Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Type
    • 9.1.1. Antipsychotic Drugs
    • 9.1.2. SSRIs/Antidepressants
    • 9.1.3. Stimulants
    • 9.1.4. Sleep Medications
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease
    • 9.2.1. Autistic Disorder
    • 9.2.2. Asperger Syndrome
    • 9.2.3. Pervasive Developmental Disorder (PDD)
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Adults
    • 9.3.2. Pediatrics
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Drug Stores & Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Type
    • 10.1.1. Antipsychotic Drugs
    • 10.1.2. SSRIs/Antidepressants
    • 10.1.3. Stimulants
    • 10.1.4. Sleep Medications
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease
    • 10.2.1. Autistic Disorder
    • 10.2.2. Asperger's Syndrome
    • 10.2.3. Pervasive Developmental Disorder (PDD)
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Adults
    • 10.3.2. Pediatrics
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Drug Stores & Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. Curemark, LLC
    • 11.2.2. Yamo Pharmaceuticals
    • 11.2.3. Pfizer Inc.
    • 11.2.4. Eli Lilly and Company
    • 11.2.5. AstraZeneca
    • 11.2.6. F. Hoffmann-La Roche Ltd
    • 11.2.7. Otsuka Holdings Co. Ltd.
    • 11.2.8. Johnson & Johnson Services, Inc.
    • 11.2.9. Teva Pharmaceutical Industries Ltd.
    • 11.2.10. H. Lundbeck A/S

List of Tables

  • Table 1: Global Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 2: Global Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 3: Global Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 4: Global Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 7: North America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 8: North America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 9: North America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 12: Europe Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 13: Europe Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 14: Europe Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 17: Asia Pacific Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 18: Asia Pacific Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 19: Asia Pacific Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 22: Latin America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 23: Latin America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 24: Latin America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 27: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 28: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 29: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Autism Spectrum Disorder Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Autism Spectrum Disorder Therapeutics Market Value Share (%), by Drug Type, 2025 & 2034
  • Figure 3: Global Autism Spectrum Disorder Therapeutics Market Value Share (%), by Disease, 2025 & 2034
  • Figure 4: Global Autism Spectrum Disorder Therapeutics Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 5: Global Autism Spectrum Disorder Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 8: North America Autism Spectrum Disorder Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 9: North America Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Disease, 2025 & 2034
  • Figure 10: North America Autism Spectrum Disorder Therapeutics Market Value Share (%), by Disease, 2025
  • Figure 11: North America Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 12: North America Autism Spectrum Disorder Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 13: North America Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Autism Spectrum Disorder Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Autism Spectrum Disorder Therapeutics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Autism Spectrum Disorder Therapeutics Market Value Share (%), By Country, 2025
  • Figure 17: Europe Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 18: Europe Autism Spectrum Disorder Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 19: Europe Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Disease, 2025 & 2034
  • Figure 20: Europe Autism Spectrum Disorder Therapeutics Market Value Share (%), by Disease, 2025
  • Figure 21: Europe Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 22: Europe Autism Spectrum Disorder Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 23: Europe Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Autism Spectrum Disorder Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Autism Spectrum Disorder Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Autism Spectrum Disorder Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 28: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 29: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Disease, 2025 & 2034
  • Figure 30: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value Share (%), by Disease, 2025
  • Figure 31: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 32: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 33: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Autism Spectrum Disorder Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 38: Latin America Autism Spectrum Disorder Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 39: Latin America Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Disease, 2025 & 2034
  • Figure 40: Latin America Autism Spectrum Disorder Therapeutics Market Value Share (%), by Disease, 2025
  • Figure 41: Latin America Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 42: Latin America Autism Spectrum Disorder Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 43: Latin America Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Autism Spectrum Disorder Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Autism Spectrum Disorder Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Autism Spectrum Disorder Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 48: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 49: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Disease, 2025 & 2034
  • Figure 50: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value Share (%), by Disease, 2025
  • Figure 51: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 52: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value Share (%), by Age Group, 2025
  • Figure 53: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Autism Spectrum Disorder Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Autism Spectrum Disorder Therapeutics Market Share (%), By Company, 2025